Metsera - Public Comps and Valuation Multiples

Metsera Overview

About Metsera

Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.

Founded

2022

HQ

Employees

Website

metsera.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$2.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Metsera Financials

Metsera has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Metsera achieved revenue of n/a and an EBITDA of -$218M.

Metsera expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Metsera valuation multiples based on analyst estimates

Metsera P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	n/a	n/a	XXX	XXX	XXX
Gross Profit	n/a	n/a	XXX	XXX	XXX
Gross Margin	NaN%	NaN%	XXX	XXX	XXX
EBITDA	-$29.4M	-$218M	XXX	XXX	XXX
EBITDA Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Profit	n/a	-$46.0M	XXX	XXX	XXX
Net Margin	NaN%	-Infinity%	XXX	XXX	XXX
Net Debt	$0.2M	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Metsera Stock Performance

As of April 15, 2025, Metsera's stock price is $18.

Metsera has current market cap of $1.9B, and EV of $2.1B.

See Metsera trading valuation data

Metsera Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.1B	$1.9B	XXX	XXX	XXX	XXX	$-11.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Metsera Valuation Multiples

As of April 15, 2025, Metsera has market cap of $1.9B and EV of $2.1B.

Metsera's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Metsera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Metsera and 10K+ public comps

Metsera Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$2.1B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	-9.7x	XXX	XXX	XXX
P/E	-9.1x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-21.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Metsera Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Metsera Valuation Multiples

Metsera's NTM/LTM revenue growth is n/a

Metsera's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.7M for the same period.

Over next 12 months, Metsera's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Metsera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Metsera and other 10K+ public comps

Metsera Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	641%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	$1.7M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
Opex to Revenue	n/a	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry